Engflag

Votripax

Quick links to important sections

Votripax

Votripax_FR

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Votripax

What is Votripax?

Votripax is a pharmaceutical medication classified as a tyrosine kinase inhibitor (TKI). It is a targeted therapy designed to interfere with specific signaling pathways that contribute to the growth and spread of certain types of cancer cells.

Mechanism of Action

The active substance in Votripax works by blocking the action of proteins known as tyrosine kinases. These proteins are found on the surface of cells and inside them, acting as chemical messengers that tell cells when to grow and divide. In some cancers, these proteins are overactive or present in high amounts, causing cells to multiply uncontrollably.

Votripax specifically targets several different kinases, including:

  • Vascular Endothelial Growth Factor Receptors (VEGFR): These are involved in angiogenesis, the process by which tumors develop their own blood supply to receive nutrients and oxygen.
  • Platelet-Derived Growth Factor Receptors (PDGFR): These play a role in cell proliferation and the development of the tumor microenvironment.
  • KIT Receptors: These are involved in the growth of certain types of solid tumors.

By inhibiting these pathways, the medication aims to slow down tumor progression and reduce the blood supply that tumors need to survive and expand.

Clinical Applications

Votripax is primarily utilized in oncology for the treatment of specific advanced malignancies. It is most commonly associated with the management of:

  • Advanced Renal Cell Carcinoma (RCC): A type of kidney cancer that has progressed or spread to other parts of the body.
  • Soft Tissue Sarcoma (STS): A group of rare cancers that develop in the tissues that support and connect the body, such as muscle, fat, blood vessels, and nerves, specifically in patients who have received prior chemotherapy.

Because Votripax is a systemic therapy, it circulates through the bloodstream to reach cancer cells throughout the body, rather than targeting a localized area like surgery or radiation.

Regulatory References

  1. B Vitamins - MedlinePlus

What side effects are possible with Votripax?

Possible Side Effects and Safety Information

The safety profile of Votripax is primarily defined by the officially documented adverse reactions associated with the Diclofenac (NSAID) component, with specific considerations for the B-vitamin complex. Regulatory documents categorize these effects based on frequency and affected body system (System-Organ Class).

Commonly Documented Adverse Reactions

Adverse reactions classified as common in official labeling frequently involve the gastrointestinal system (e.g., nausea, abdominal pain, diarrhea) and the central nervous system (e.g., headache, dizziness). Reactions at the injection site are also a common characteristic of the injectable formulation.

Serious Adverse Reactions and High-Level Risks

The regulatory profile documents the potential for rare but serious, potentially fatal adverse reactions. These include the risks of major Gastrointestinal Bleeding, Ulceration, or Perforation, and serious Arterial Thrombotic Events such as Myocardial Infarction (heart attack) and Stroke. Additionally, very rare serious reactions include severe skin conditions like Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Duration and Population-Specific Safety Patterns

Official safety statements note that the risk of serious cardiovascular and gastrointestinal events typically increases with the duration of use and higher dosage. Furthermore, elderly patients are recognized as being at a greater risk for developing serious adverse reactions. A specific, long-term safety constraint related to the B-vitamin component is the risk of Peripheral Neuropathy, which is associated with prolonged, high-dose use of Pyridoxine (B6).

Safety Restrictions

The medicine is officially restricted in certain clinical situations, including active gastrointestinal bleeding or ulceration, a history of NSAID-induced severe allergic reactions, and severe hepatic, renal, or heart failure. These limitations are clearly defined in regulatory prescribing information.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for this combination drug addresses the distinct toxicological risks documented in regulatory labeling. Overdose exposure may result in common gastrointestinal symptoms (e.g., nausea, vomiting, abdominal pain) and Central Nervous System effects such as dizziness or headache. More severe manifestations linked to the Diclofenac component include Gastrointestinal Perforation, Acute Renal Failure, Hepatotoxicity, Convulsions, and Coma.

The injectable B-vitamin components carry a documented risk of Anaphylactic Shock and Pulmonary Edema. Regulatory labeling mandates that patients seek immediate medical attention for any suspected overdose or when severe symptoms, such as bleeding or difficulties with breathing, occur.

Management is strictly confined to symptomatic and supportive treatment because no specific antidote is known for the primary toxic component. Elderly patients are officially noted to be at a greater risk for severe gastrointestinal events. Furthermore, continuous hospital monitoring of organ function is required to address potential acute damage, and long-term, high exposure to Pyridoxine is associated with Peripheral Sensory Neuropathy.

Therapeutic Uses of Votripax

What Votripax Treats: Main Uses and Benefits

The primary therapeutic focus of Votripax may be applied as part of a strategy to help ease symptoms in clinical settings marked by significant pain and nerve-related discomfort, offering a dual therapeutic strategy that helps manage both inflammation and symptoms related to nerve irritation.

Combination therapy using diclofenac with B vitamins (thiamine, pyridoxine, and cyanocobalamin) is used to provide comprehensive symptomatic relief in acute low back pain and painful vertebral syndromes.

Managing Acute and Severe Musculoskeletal Inflammation

This formulation is commonly used to help with pronounced symptoms associated with degenerative rheumatic disorders and osteoarthritis, particularly when the pain and inflammation are acute or moderate-to-severe. It is applied during episodes of sudden symptom escalation, such as an acute flare-up of low back pain or a period of heightened discomfort in major joints. Used for managing pain in conditions such as painful vertebral syndromes, lumbosacral radiculopathy, and osteoarthritis. This supportive relief helps patients cope more steadily with difficult episodes.

“The approach is relevant in contexts marked by increased discomfort and is typically applied in scenarios where additional management of discomfort is required.”

Symptomatic Relief for Mixed Pain and Nerve Irritation

Votripax is relevant in clinical settings where the symptomatic presentation involves both tissue inflammation and peripheral nerve irritation (neuralgia or neuritis). The approach is relevant for easing symptoms that interfere with daily functioning while providing additional support for symptom management in nerve-related contexts. This approach is relevant for managing the overall symptom burden and may assist with maintaining day-to-day comfort during periods of functional strain.

Quick Fact: Relief for Acute Pain
Common Use: Applied for conditions characterized by periods of heightened symptoms, such as sudden, severe flare-ups of lower back pain or joint discomfort.
Key Benefit: Contributes to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable.

Regulatory References

  1. NIH PubMed Central Systematic Review

Eligibility and Restrictions for Use

Votripax eligibility is strictly defined by the regulatory profile of its Diclofenac (NSAID) component, as documented by global health authorities, and is intended for use only in the adult population.

Contraindicated Populations and Conditions

Votripax must not be used by individuals presenting with the following official exclusions:

  • Hypersensitivity to diclofenac, aspirin, other NSAIDs, or any component of the drug product.
  • Active gastrointestinal ulceration, bleeding, or perforation, or a history of recurrent peptic ulcers.
  • Severe organ failure, including severe hepatic failure or severe renal failure.
  • Established congestive heart failure (NYHA Class II–IV), ischemic heart disease, peripheral arterial disease, or cerebrovascular disease.
  • In the setting of Coronary Artery Bypass Graft (CABG) surgery.
  • Women in the last trimester of pregnancy (starting at approximately 30 weeks' gestation).

Age and Conditional Use Rules

  • Pediatric Use: The medicine is not recommended for use in children and adolescents (under 18 years of age) due to the dosage strength of the injection and a lack of established safety data.
  • Geriatric Use: Caution is required for elderly patients, who are at a greater risk of serious adverse events; the lowest effective dose is advised.
  • Conditional Use: Patients with mild to moderate hepatic or renal impairment, uncontrolled hypertension, or those with significant cardiovascular risk factors should use the medicine only after careful consideration and under close medical surveillance.

What should I know about interactions with other medicines?

Votripax Interactions with other medicines and products

The interaction profile for Votripax, which contains Diclofenac (an NSAID) and a B-Vitamin complex, is officially documented to involve both pharmacokinetic and pharmacodynamic effects on co-administered substances. Regulatory sources state that the use of Votripax is contraindicated for the treatment of perioperative pain related to coronary artery bypass graft (CABG) surgery and should be avoided with other systemic NSAIDs due to the risk of additive undesirable effects.

Interaction Type Interacting Substance Categories Regulatory Outcome
Pharmacodynamic Anticoagulants, Antiplatelets, SSRIs, Antihypertensives Increased risk of bleeding or diminished therapeutic effect of co-administered drug.
Pharmacokinetic CYP2C9 Inhibitors (e.g., Voriconazole), Digoxin Co-administration may increase plasma concentration (AUC/Cmax) of Diclofenac or Digoxin.

The B-Vitamin components (Pyridoxine and Cyanocobalamin) also have specific interactions. Pyridoxine may officially decrease the blood levels and reduce the efficacy of Levodopa. Furthermore, regulatory documentation notes that heavy alcohol intake over two weeks may produce malabsorption of Cyanocobalamin (B12). Specific population constraints exist, noting that the risk of renal deterioration is heightened when Diclofenac is co-administered with ACE Inhibitors or ARBs in elderly or renally impaired patients.

Mechanism of Action

Enzyme Inhibition in Inflammatory Signaling

The anti-inflammatory component works by acting as an inhibitor of Cyclooxygenase (COX) enzymes . This molecular blockade suppresses the chemical mediators that sensitize peripheral pain receptors, resulting in a physiological reduction in the local inflammatory signaling process.

Neurotrophic Cofactor Activity

The high-dose B-Vitamin complex provides essential cofactors for key enzymes (like Methionine Synthase) that maintain neuronal energy metabolism and structural integrity. This mechanism provides metabolic support necessary for the structural integrity and cellular function of nerve tissue.

Synergistic Modulation of Pain Pathways

The drug’s combined mechanism involves Diclofenac modulating peripheral inflammatory signaling, while the B-Vitamins contribute by modulating pain-transmitting neural receptors and activity within central inhibitory pathways. This dual, complementary action leads to a synergistic antinociceptive effect, demonstrating functional potentiation within the pain signaling pathways.

Dosage and Administration Information

Recommended Dosing and Administration

Votripax (pazopanib) is a kinase inhibitor typically administered to treat advanced renal cell carcinoma or advanced soft tissue sarcoma. The recommended starting dose is 800 mg taken orally once daily.

Important Administration Instructions

  • Food Intake: Votripax must be taken without food. Administration should occur at least one hour before or two hours after a meal to ensure consistent absorption.
  • Tablet Integrity: Swallow tablets whole. Do not crush or chew the Votripax tablets, as this can increase the rate of absorption and potentially affect systemic exposure.
  • Missed Dose: If you miss a dose, do not take it if the next scheduled dose is less than 12 hours away. Resume the regular dosing schedule with the next planned dose.

Dosage Modifications

Your healthcare provider may adjust the dose based on your individual tolerability and specific medical conditions, such as liver function. The daily dose should not exceed 800 mg. For patients with moderate hepatic impairment at baseline, the recommended starting dose is reduced to 200 mg once daily, and the use of Votripax is generally not recommended for those with severe hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Votripax (Diclofenac/B-Vitamins)

Evidence for use in Acute Low Back Pain and Vertebral Syndromes

Research has explored the combination of Diclofenac and B-Vitamins (Thiamine, Pyridoxine, and Cyanocobalamin) in patients with acute low back pain (LBP) and other painful conditions affecting the spine. These investigations often took the form of short-term Randomized Controlled Trials (RCTs), with findings aggregated in Systematic Reviews and Meta-Analyses. These studies was studied for use in acute low back pain by comparing the combination formulation to Diclofenac alone, during periods of increased symptom activity.

The core evidence research examined outcomes related to time until patients met the criteria for sufficient symptom relief and changes in their pain intensity and mobility scores. Studies report patterns where the combination was associated with time measurements where patients met the criteria for adequate symptom relief. Findings indicate that in some instances, the combination was observed in studies to be linked to measured symptom intensity scores at early check-in points.

Evidence for use in Acute Inflammatory and Post-Traumatic Pain

Votripax was studied for use in specific acute inflammatory or irritative states, such as severe osteoarthritis flare-ups or pain following trauma or surgery. These research scenarios focused on research exploring short-term symptom changes, often involving small-scale pilot studies and short-duration RCTs.

Studies also monitored outcomes related to analgesic consumption during the immediate observation period. Trials data show patterns related to measurements of analgesic consumption compared to Diclofenac monotherapy over a very short monitoring window (e.g., 24 hours). Findings describe patterns where the combination may be associated with symptom intensity scores that were monitored compared to Diclofenac alone during the very acute phase of discomfort.

Long-Term Studies and Research Gaps

The majority of the research exploring the Diclofenac and B-Vitamin combination research examined acute symptom patterns, meaning that follow-up durations were limited. Consequently, there is limited information for long-term outcomes. The long-term effects are not fully established, and existing studies provide limited insight into how the combination may affect recurrence rates or provide sustained support for symptoms over many months or years. Evidence for ongoing, stable, or chronic pain management is limited or insufficient in the existing body of research. Data for certain groups, such as older adult patients or pediatric populations, also remain insufficient.

Key Studies & References

  1. Effect of Combined Diclofenac and B Vitamins (Thiamine, Pyridoxine, and Cyanocobalamin) for Low Back Pain Management: Systematic Review and Meta-analysis.
  2. B-vitamin Mixture Improves the Analgesic Effect of Diclofenac in Patients with Osteoarthritis: A Double Blind Study (Acute Inflammatory Pain Model).

Frequently Asked Questions (FAQ)

Common questions about Votripax (FAQ)

Q: How quickly does Votripax start working for most people?

Studies on the main component, diclofenac, indicate an onset of action that can range from as quickly as 30 minutes up to within four hours, depending on the specific product formulation. Official information suggests that the expected onset of effect typically falls within this general timeframe.

Q: Does taking Votripax affect driving or operating machinery?

Regulatory documents advise caution for activities that require full attention. If side effects like dizziness, vertigo, or lightheadedness occur while using Votripax, it is advised that activities requiring attention, such as driving or operating machinery, be avoided until those effects have passed. This is a standard precaution for medicines that may cause central nervous system effects.

Q: Is Votripax known to interact with common pain relievers?

Official information states that the diclofenac component should not be taken with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen or naproxen. However, it is generally described as compatible with non-NSAID pain relievers, such as acetaminophen (paracetamol).

Q: Can Votripax be taken during pregnancy?

Official documents strictly contraindicate the use of the diclofenac component in the last trimester of pregnancy, which begins around 30 weeks. Use is generally not recommended during other stages of pregnancy unless specifically directed and carefully considered by a healthcare provider.

Q: Is Votripax considered safe to use while breastfeeding?

Data suggests that only small amounts of the diclofenac component may pass into breast milk, and it is generally described as compatible with breastfeeding by some medical sources. Information regarding use during this period should always be confirmed with a healthcare provider.

Q: Are there any known issues with Votripax and kidney or liver function?

Official documents state the medicine is strictly contraindicated for individuals with severe hepatic (liver) or severe renal (kidney) failure. Additionally, official labeling notes that dose modification is specified for patients with moderate hepatic impairment.

Q: How long after stopping Votripax does the drug typically stay in the system?

The main component, diclofenac, has a short elimination half-life, which is the time it takes for half of the drug to be cleared from the body. This is typically described in official documents as being between 1.2 to 2 hours.

Q: What is the typical time frame for a full course of Votripax treatment?

Votripax is intended and studied for the management of acute (sudden and short-term) symptom patterns. For this reason, research and official sources describe its use primarily for short-term courses and not for chronic (ongoing) pain management.

Q: What is the meaning of the warning label on Votripax?

Regulatory agencies use special warnings (often called 'boxed warnings') to highlight the potential for rare but serious adverse reactions. For this class of medicine, this officially includes the risks of serious gastrointestinal bleeding or ulceration and serious cardiovascular thrombotic events like heart attack or stroke.

Q: Can I take Votripax if I am taking over-the-counter vitamins?

Official documents advise caution, as general vitamins and supplements are not always formally tested for interaction in the same way as prescription medicines. Any decision regarding co-administration of supplements should be made in consultation with a healthcare provider.

Q: Is Votripax considered a strong medicine?

Official documents classify Votripax as a multicomponent analgesic (pain reliever) and anti-inflammatory agent. The diclofenac component is officially described as a potent Non-Steroidal Anti-Inflammatory Drug (NSAID).

Q: Is Votripax similar to other drugs I might have heard of?

Votripax is a combination drug that contains Diclofenac, which belongs to the class of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). This is a large category that includes several other commonly known medicines used to relieve pain and inflammation.

Q: What is the difference between Votripax and [Name of similar drug]?

Votripax is officially defined as a combination drug because it contains a dual formulation. It includes Diclofenac (the anti-inflammatory component) combined with a high-dose B-Vitamin Complex, which distinguishes it from products that contain only a single NSAID ingredient.

Q: Can Votripax cause a change in mood or energy levels?

Official adverse event data for the diclofenac component includes reports of certain central nervous system effects. These reports include experiences such as anxiety, depression, and asthenia, which is a medical term for a lack of energy.

Q: What happens if I forget to take Votripax?

For the oral tablet form, official administration instructions specify a rule for a missed dose. A missed dose should not be taken if the next scheduled dose is less than 12 hours away; instead, the regular schedule should be resumed with the next planned dose.

Q: Is it common to feel a little dizzy when first starting Votripax?

Dizziness is listed as a commonly documented adverse reaction in official product information. Sources note that for some patients, these types of effects may lessen as the body adjusts to the medicine.

Q: Can Votripax be used by people who have heart conditions?

The medicine is strictly contraindicated for people with established serious heart conditions, such as congestive heart failure (NYHA Class II–IV), ischemic heart disease, or cerebrovascular disease. Patients with other significant cardiovascular risk factors require careful consideration.

Q: Are there age limits for using Votripax?

Official documents state that the medicine is intended for the adult population and is not recommended for use in children and adolescents (under 18 years of age). Caution is also advised when the medicine is used by elderly patients.

Q: Is Votripax a treatment for symptoms or the underlying cause?

Votripax is officially defined as a multicomponent analgesic and anti-inflammatory agent. Its primary purpose is generally described in official sources as providing relief from pain and nerve-related discomfort, meaning it treats the symptoms rather than the primary underlying disease.

Q: Do official documents mention any risk of dependence with Votripax?

Votripax is not classified by regulatory agencies as a controlled substance. The active components, Diclofenac (an NSAID) and B-Vitamins, are not described in official documents as carrying a risk of dependence or abuse potential.

Q: Is it true that Votripax can cause insomnia?

Insomnia is listed in official adverse event data for the diclofenac component. It is reported as one of the experiences recorded occasionally in regulatory databases.

Q: Does Votripax affect blood pressure?

Regulatory warnings note that the NSAID component may counteract the effect of certain blood-pressure-lowering drugs. NSAIDs as a class may also cause an increase in blood pressure in some patients, particularly those with pre-existing hypertension.

How should Votripax be stored and disposed of?

How to Store and Dispose of Votripax?

Regulatory agencies define specific conditions to maintain the stability of the Votripax solution (Diclofenac and B-Vitamins). Adhering to these official rules is mandatory and relates strictly to temperature, light protection, and disposal.

Storage Requirement Official Condition (Regulatory Labeling)
Temperature Range Store the product at or below 30 C (e.g., controlled room temperature).
Light & Packaging Must be protected from light; keep the ampoules in the original outer carton until use.
Handling Prohibition Do not freeze the solution, as this may affect the integrity of the parenteral components.
Child Safety Keep the medicine out of the sight and reach of children.

Because Votripax is a sterile injection often mixed just before use, any prepared solution should be used immediately. Unused or expired Votripax and associated sharps (needles/syringes) must be disposed of safely. The preferred method is a formal drug take-back program or mail-back service. If a take-back option is unavailable, the medicine should be mixed with an undesirable substance (e.g., used coffee grounds, dirt) and placed in a sealed container before discarding in the household trash, following local regulations. Do not dispose of the solution down the sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Votripax found in:

A-Z Index: